16097-64-6

Usage

Uses

Used in Pharmaceutical Industry:
2,4-dichloro-6-(trifluoromethyl)pyrimidine is used as a synthetic intermediate for the development of 2,4-diaminopyrimidines derivatives. These derivatives exhibit antiplasmodial activities, making them valuable in the creation of new drugs to combat malaria and other related diseases. The compound's unique structure allows for the design of novel therapeutic agents with improved efficacy and reduced side effects.
Used in Chemical Synthesis:
In the field of organic chemistry, 2,4-dichloro-6-(trifluoromethyl)pyrimidine serves as a versatile building block for the synthesis of a wide range of chemical compounds. Its reactivity and functional groups enable chemists to create diverse molecules with various applications, such as agrochemicals, dyes, and other specialty chemicals. The compound's trifluoromethyl group, in particular, is known for its unique properties and can impart valuable characteristics to the synthesized products.

Synthesis Reference(s)

Journal of Heterocyclic Chemistry, 24, p. 1243, 1987 DOI: 10.1002/jhet.5570240502

InChI:InChI=1/C5HCl2F3N2/c6-3-1-2(5(8,9)10)11-4(7)12-3/h1H

Upstream product

• 102-82-9 tributyl-amine 
• 672-45-7 6-Trifluoromethyluracil 
• 85730-34-3 4-Chloro-6-trifluoromethylpyrimidin-2-yldichlorophosphate 
• 121-44-8 triethylamine 
• 672-45-7 6-trifluoromethyluracil 
• 16097-63-5 4-Chloro-2-methylthio-6-(trifluoromethyl)pyrimidine 
• 16097-62-4 4-hydroxy-2-(methylthio)-6-(trifluoromethyl)pyrimidine 
• 93669-61-5 4-N-Methylanilino-2-methylthio-6-trifluoromethylpyrimidine 
• 368-54-7 6-trifluoromethyl-4-hydroxy-2-mercaptopyrimidine 
• 121-69-7 N,N-dimethyl-aniline 
• 85730-37-6 4-Amino-6-trifluoromethylpyrimidin-2-ol Hydrochloride 
• 102-69-2 tri-n-propylamine 

Downstream Products

• 93669-58-0 2-Chloro-4-N-methylanilino-6-trifluoromethylpyrimidine 
• 93669-54-6 2,4-bis(N-Methylanilino)-6-trifluoromethylpyrimidine 
• 114963-95-0 2-chloro-4-ethoxy-6-(trifluoromethyl)pyrimidine 
• 85730-36-5 4-Amino-2-chloro-6-trifluoromethylpyrimidine 
• 16097-60-2 2-amino-4-chloro-6-(trifluoromethyl)pyrimidine 
• 1111129-76-0 C₁₁H₇ClF₃N₃ 
• 1250867-97-0 3-(2-chloro-6-trifluoromethyl-pyrimidin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane 
• 1138153-64-6 (2-chloro-6-trifluoromethylpyrimidin-4-yl)-methyl-(4-trifluoromethoxyphenyl)-amine 
• 2102501-84-6 [(1R,5S,6R)-3-{2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid 

Relevant academic research and scientific papers

HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 R2, R4 and X1 are defeined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Spirocyclic derivatives

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.

N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R9a, R9b, R9c, R9d, R9e, R9f, m, n, A, L and B are as defined herein.

METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.

HEPATITIS B VIRAL ASSEMBLY EFFECTORS

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

ANTIVIRAL PYRIMIDINES

Disclosed herein are novel compounds comprising substituted pyrimidines, pyrazolopyrimtdines, and imidazolopyrimidines, the syntheses thereof, and compositions thereof, including pharmaceutical compositions, comprising the novel pyrimidines, pyrazolopyrimtdines, imidazolpyrimidines and related compounds. Such compounds function to inhibit entry of viruses of the Flaviviridae family, including Hepatitis C virus (HCV), into cells that are susceptible to virus infection. These compounds are useful for the treatment, therapy and/or prophylaxis of viral diseases and infection, including HCV infection.

INSECTICIDAL PYRIMIDINYL ARYL HYRDRAZONES

Pyrimidinyl aryl hydrazones are effective at controlling insects.

Metal-bearing and trifluoromethyl-substituted pyrimidines: Generation and functionalization

5-Pyrimidyllithium species are fairly stable when the metal is flanked by two electron-withdrawing substituents such as trifluoromethyl and chlorine or bromine. Thus, the corresponding 5-carboxylic acids are produced in high yields from 4,5-dibromo-6-(trifluoromethyl)pyrimidine and 5-bromo-4-chloro-6- (trifluoromethyl)pyrimidine upon halogen/metal permutation accomplished with isopropylmagnesium chloride or butyllithium followed by carboxylation. Satisfactory or excellent yields of 5-carboxylic acids are equally obtained when 4-chloro-, 2,4-dichloro- and 2,4-dibromo-6-(trifluoromethyl)pyrimidine are deprotonated with lithium diisopropylamide before being allowed to react with dry ice. In contrast, consecutive treatment of 2-bromo-4-(trifluoromethyl) pyrimidine and 2-chloro-5-iodo-4-(trifluoromethyl)pyrimidine with butyllithium affords the expected carboxylic acids in only poor yields and not even trace amounts of acid were detected when 4-bromo-6-(trifluoromethyl)pyrimidine served as the substrate. The formation of bipyrimidines, emerging from either one of two competing mechanistic pathways, is a permanently menacing side reaction. Wiley-VCH Verlag GmbH & Co. KGaA, 2006.

COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS

The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.

Pyrimidines.9.Chlorination of 6-Trifluoromethyluracil with Phosphorus Oxychloride in the Presence of Trialkylamines

Ring-chlorination of 6-trifluoromethyluracil in phosphorus oxychloride in the presence of triethyl, tri-n-propyl, and tri-n-butylamines was studied with respect to by-product formation.Comparisons were made with the results obtained by treating the prefor